Form 8-K - Current report:
SEC Accession No. 0001193125-25-042498
Filing Date
2025-02-28
Accepted
2025-02-28 16:15:28
Documents
14
Period of Report
2025-02-28
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d926755d8k.htm   iXBRL 8-K 36981
2 EX-99.1 d926755dex991.htm EX-99.1 10063
  Complete submission text file 0001193125-25-042498.txt   172963

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA syrs-20250228.xsd EX-101.SCH 2843
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE syrs-20250228_lab.xml EX-101.LAB 17234
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE syrs-20250228_pre.xml EX-101.PRE 10807
16 EXTRACTED XBRL INSTANCE DOCUMENT d926755d8k_htm.xml XML 3499
Mailing Address 35 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140
Business Address 35 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140 617-744-1340
Syros Pharmaceuticals, Inc. (Filer) CIK: 0001556263 (see all company filings)

EIN.: 453772460 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37813 | Film No.: 25690405
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)